PXS25 — targeting lung fibrosis
Our most advanced new drug candidate, PXS25, is being developed to treat interstitial lung disease such as pulmonary fibrosis. The safety testing is finished and PXS25 will be ready for its first clinical investigational study in humans after the development of a sensitive assay to detect PXS25 in humans is complete. The Phase I clinical study will be conducted in Australia and will focus on safety and the pharmacokinetic profile of PXS25.
PXS4159 — promising new candidate for asthma
In another research project, our drug discovery team has now designed a large library of small molecules that inhibit a critical protein that is implicated in the inflammatory response and organ damage associated with chronic immune mediated diseases such as asthma. We have selected a development candidate PXS4159 and have begun the scale up manufacture and pre-clinical safety studies necessary prior to evaluating the compound in human studies. In parallel, we continue basic research to explore its other potential clinical uses.
